Janssen teams up with Nuevolution on drug discovery

19 October 2015

Danish biotech company Nuevolution has entered into a collaboration with Janssen Biotech, one of the Janssen Pharmaceutical companies of Johnson & Johnson (NYSE: JNJ).

Nuevolution is a privately-held biotech company based in Copenhagen, and applies its proprietary drug discovery platform to novel small molecule therapeutics. The collaboration with Janssen will be multi-target, and will focus on the discovery and development of therapies to treat oncological, infectious and inflammatory diseases.

Nuevolution will apply its drug discovery platform Chemetics to discover and advance candidates against targets of interest to Janssen. As per the agreement, Nuevolution will receive an upfront payment, research funding and would be eligible to milestone payments upon achievement of specified research, development and commercial milestones. It would also be entitled to certain royalty payments on net-sale of products commercialized as a result of the collaboration.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK